NYSE$DVA

DaVita HealthCare Partners Inc · Q3 2022 earnings

Q3 2022 earnings · · Investor relations

Briefing

DaVita's financial performance was impacted by negative volume trends due to COVID and continued labor pressure.

DaVita Inc. reported consolidated revenues of $2.949 billion, operating income of $312 million, and diluted earnings per share of $1.13 for the quarter ended September 30, 2022. The company repurchased 2.1 million shares of its common stock at an average cost of $87.10 per share. The third quarter was challenging due to COVID and labor pressures.

  • Consolidated revenues were $2.949 billion.
  • Operating income was $312 million and adjusted operating income was $351 million.
  • Diluted earnings per share was $1.13 and adjusted diluted earnings per share was $1.45.
  • Operating cash flow and free cash flow were $711 million and $500 million, respectively.

Headline financials

Total Revenue

$2.95B

Previous: $2.94B+0.4%
EPS (adj)

$1.45

Previous: $2.36-38.6%
U.S. Dialysis Treatments

7.3M

Previous: 7.5M-1.7%
U.S. Dialysis Avg Treatments per Day

92.9K

Previous: 94.5K-1.7%
U.S. Dialysis Avg Revenue per Treatment

$367.67

Previous: $360.54+2.0%
Capital Expenditures

-$409M

Previous: -$452M+9.4%
Free Cash Flow

-$304M

Previous: -$192M-58.2%
Net Income

$105M

Previous: $260M-59.4%
Operating Income

$312M

Previous: $475M-34.3%
Gross Profit

$2.95B

Previous: $2.94B+0.4%
Cash & Equivalents

$368M

Previous: $1.05B-64.9%
Total Assets

$17B

Previous: $17.6B-3.8%
Stock-Based Comp

$27.8M

Previous: $24.2M+14.9%

Revenue & EPS history

DaVita · Revenue · Quarterly

$2.95B

Q3 2022+0.4%vs Q3 2021
Beat estimate in 9 of 15 quarters(60%)
ActualEstimate

Revenue by segment

DaVita · $2.97B total across 3 segments · Q3 2022

  • U.S. Dialysis Patient Services
    $2.7B
  • International Dialysis Patient Service
    $175M-33.2%
  • Integrated Kidney Care
    $87M

Forward guidance

DaVita provided adjusted operating income, adjusted diluted net income per share attributable to DaVita Inc., and free cash flow guidance for 2022.

Tailwinds

  • Absence of ballot initiative expenses: $60 million
  • Integrated Kidney Care: -$25 to $0 million
  • Treatment volume growth: -$200 to $0 million
  • Revenue per treatment growth: $200 to $250 million
  • Cost savings initiatives: $125 to $175 million

Headwinds

  • Labor pressure and inflation: -$300 to -$250 million

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2022

Historical avgQ3 2022

+0.2%

Avg return

Earnings day

+0.5%

Avg return

5 days after

+1.6%

Avg return

30 days after

54%

39 / 72 earnings

Positive

+14.7%

Q3 2019

Best reaction

-24.5%

Q3 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.6%+22.2%+22.4%
Q4 2025+11.0%+26.7%+34.9%
Q3 2025-6.0%-5.2%-5.4%
Q1 2025-0.2%+0.7%-4.9%
Q4 2024-11.1%-12.5%-19.0%
Q3 2024-10.1%-9.8%+5.5%
Q2 2024-1.1%+3.6%+9.8%
Q1 2024-3.8%-1.5%+5.3%
Q4 2023+8.0%+6.9%+19.0%
Q3 2023+7.4%+5.1%+33.9%
Q2 2023+6.7%+8.6%+1.0%
Q1 2023+13.8%+5.9%+13.7%
Q4 2022-0.3%-0.3%-8.4%
Q3 2022-24.5%-27.9%-23.6%
Q2 2022+2.7%+1.8%+1.3%
Q1 2022-7.1%-5.0%-12.7%
Q4 2021-1.2%+3.5%-2.6%
Q3 2021-6.9%-6.2%-12.3%
Q2 2021+10.2%+9.7%+10.0%
Q1 2021+2.8%+8.9%+6.0%
Q4 2020-7.4%-8.1%-4.4%
Q3 2020-0.0%+7.7%+27.4%
Q2 2020-4.3%-8.5%-4.8%
Q1 2020+9.6%+7.5%+9.7%
Q4 2019+8.8%+5.7%-8.0%
Q3 2019+14.7%+13.6%+17.9%
Q2 2019+0.4%-1.5%-5.8%
Q1 2019-10.4%-9.8%-19.4%
Q4 2018+1.3%+3.0%-6.7%
Q3 2018+1.3%-1.5%-14.9%
Q2 2018+5.4%+3.9%-1.4%
Q1 2018+4.7%+1.2%+5.9%
Q4 2017+1.8%+0.3%-5.4%
Q3 2017-8.5%-7.4%+13.0%
Q2 2017-9.8%-10.9%-9.6%
Q1 2017-3.8%-5.3%-2.4%
Q4 2016+3.2%+6.2%+4.5%
Q3 2016+1.1%+0.1%+11.1%
Q2 2016-6.0%-10.1%-16.4%
Q1 2016+2.9%
Q4 2015-1.7%
Q3 2015-0.9%
Q2 2015+1.0%
Q1 2015-1.1%
Q4 2014-3.8%
Q3 2014-3.9%
Q2 2014+0.1%
Q1 2014-2.8%
Q4 2013+3.9%
Q3 2013-3.0%
Q2 2013-2.9%
Q1 2013+9.4%
Q4 2012-1.1%
Q3 2012+1.4%
Q2 2012-1.1%
Q1 2012-4.9%
Q4 2011+0.3%
Q3 2011+0.8%
Q2 2011-0.2%
Q1 2011+2.9%
Q4 2010+2.4%
Q3 2010-0.4%
Q2 2010+3.3%
Q1 2009+1.1%
Q1 2010+0.3%
Q4 2009-0.1%
Q3 2009+0.1%
Q3 2008+0.1%
Q2 2008+4.6%
Q4 2008+4.6%
Q2 2009+4.6%
Q4 2007+4.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro